aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in New York City, Hookipa Pharma is a clinical-stage biotech company dedicated to developing advanced immunization therapies for infectious diseases and oncology. Their core mission is to harness the power of the immune system to create best-in-class treatments that offer superior efficacy and safety. Hookipa's innovative approach focuses on leveraging CD8+ T cells to target and destroy cancer cells, as well as combat infectious pathogens. The company aims to revolutionize the landscape of immunotherapy through its cutting-edge research and development.
Hookipa Pharma has garnered attention from notable investors and industry leaders, contributing to its rapid growth and recognition in the biotech sector. The company's key achievements include presenting positive clinical data at prestigious conferences such as the American Society of Clinical Oncology. These milestones underscore Hookipa's potential to make significant impacts in the fields of infectious disease and cancer treatment. Through their pioneering work, Hookipa Pharma is poised to transform immunotherapy, offering new hope to patients worldwide.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Cancer Therapies, Immunotherapy
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Software, Biotech
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
Global
When was Hookipa Pharma founded?
Hookipa Pharma was founded in 2011.
Where is Hookipa Pharma’s headquarters located?
Hookipa Pharma’s headquarters is located in Wilmington, DE, US.
When was Hookipa Pharma’s last funding round?
Hookipa Pharma’s most recent funding round was for $21.3M (USD) in December 2023.
How many employees does Hookipa Pharma have?
Hookipa Pharma has 136 employees as of Feb 6, 2024.
How much has Hookipa Pharma raised to-date?
As of July 05, 2023, Hookipa Pharma has raised a total of $284.8M (USD) since Dec 21, 2023.
Add Comparison
Total Raised to Date
$284.8M
USD
Last Update Dec 21, 2023
Last Deal Details
$21.3M
USD
Dec 21, 2023
Post Ipo Equity
Total Employees Over Time
136
As of Feb 2024
Hookipa Pharma Address
251 Little Falls Drive
Wilmington,
Delaware
19808
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts